Lupin Ltd has acquired Mexico’s speciality pharmaceutical company Laboratorios Grin, for an undisclosed sum. The move marks Lupin’s entry into the Mexican and larger Latin American market.
Mexico is one of the fast-growing pharmaceutical markets, valued at over $13.5 billion and growing at 9-10 per cent annually.
Incorporated in 1955, Grin makes and sells branded ophthalmic products, and recorded revenues of approximately $28 million in 2013. The company has over 275 employees.
Vinita Gupta, Lupin’s Chief Executive Officer, said the acquisition is a reflection of Lupin’s commitment to expand into the Latin American market and build its global specialty business. “We see a lot of synergies in this acquisition and plan to bring our ophthalmic pipeline to build the Grin business as well as leverage their commercial presence to enter other promising therapy segments,” she said in a company statement.
Mumbai, May 22, 2024: The Department of Nursing at S.L. Raheja Hospital, Mahim - A…
Hubli, May 20, 2024: In a significant move to support child nutrition through effective logistical contributions,…
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…